{"id":"copd-rescue-medications","safety":{"commonSideEffects":[{"rate":"5-15%","effect":"Tremor"},{"rate":"5-10%","effect":"Tachycardia"},{"rate":"5-10%","effect":"Headache"},{"rate":"3-8%","effect":"Nervousness/anxiety"},{"rate":"2-5%","effect":"Palpitations"},{"rate":"2-5%","effect":"Muscle cramps"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These medications bind to beta-2 adrenergic receptors on airway smooth muscle, triggering rapid bronchodilation within minutes. They are used as needed for acute symptom relief during COPD exacerbations or breakthrough symptoms, providing temporary improvement in airflow and breathing. Common examples include albuterol (salbutamol) and levalbuterol.","oneSentence":"COPD rescue medications are short-acting beta-2 agonists (SABAs) that rapidly relax airway smooth muscle to provide quick relief of acute bronchospasm and breathing difficulty.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:22.910Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD)"},{"name":"Rescue therapy for acute dyspnea and airway obstruction in COPD patients"}]},"trialDetails":[{"nctId":"NCT06376994","phase":"PHASE3","title":"Multi-Center Clean Air Randomized Controlled Trial in COPD","status":"RECRUITING","sponsor":"JHSPH Center for Clinical Trials","startDate":"2024-05-24","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":770},{"nctId":"NCT04821869","phase":"","title":"ProAir Digihaler in COPD Disease Management: A Real World Study","status":"COMPLETED","sponsor":"Pulmonary Research Institute of Southeast Michigan","startDate":"2021-05-10","conditions":"COPD, COPD Exacerbation Acute","enrollment":27},{"nctId":"NCT02386722","phase":"NA","title":"Intervention to Improve Inhalative Adherence","status":"COMPLETED","sponsor":"Cantonal Hosptal, Baselland","startDate":"2014-01","conditions":"Chronic Asthma, COPD","enrollment":169},{"nctId":"NCT04166344","phase":"NA","title":"A MHealth Intervention to Improve Symptom Control in Children and Adolescents with Difficult-to-control Asthma","status":"COMPLETED","sponsor":"Lovexair Foundation","startDate":"2021-09-01","conditions":"Asthma in Children","enrollment":60},{"nctId":"NCT04795323","phase":"PHASE2","title":"Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-04-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":5},{"nctId":"NCT03256695","phase":"PHASE3","title":"Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2017-09-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":405},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03345407","phase":"PHASE2","title":"Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":943},{"nctId":"NCT03250689","phase":"PHASE2","title":"Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19},{"nctId":"NCT04694430","phase":"","title":"A Multi-center Study to Determine the Prevalence and Influence of Pertussis on COPD Exacerbation in Shenzhen","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2021-01-01","conditions":"COPD Exacerbation, Pertussis","enrollment":500},{"nctId":"NCT03357341","phase":"","title":"Sensor and Electronic Health Records (EHR) Integration Pilot Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":194},{"nctId":"NCT03034967","phase":"PHASE2","title":"Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-04-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":614},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT03467425","phase":"PHASE4","title":"INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3109},{"nctId":"NCT03170232","phase":"PHASE2","title":"A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-10-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":54},{"nctId":"NCT02573870","phase":"PHASE2","title":"Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-12-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":63},{"nctId":"NCT02371629","phase":"PHASE4","title":"A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":776},{"nctId":"NCT02729051","phase":"PHASE3","title":"Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1055},{"nctId":"NCT00441701","phase":"PHASE2","title":"Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":99},{"nctId":"NCT01006616","phase":"PHASE2","title":"Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-01","conditions":"COPD","enrollment":616},{"nctId":"NCT02275052","phase":"PHASE4","title":"A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":198},{"nctId":"NCT02299375","phase":"PHASE2","title":"Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":184},{"nctId":"NCT03363191","phase":"PHASE4","title":"The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2018-03-07","conditions":"Asthma","enrollment":""},{"nctId":"NCT02257372","phase":"PHASE4","title":"A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT01313494","phase":"PHASE3","title":"A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-03","conditions":"COPD","enrollment":626},{"nctId":"NCT02706600","phase":"NA","title":"Trial of E-Health Platform Supported Care vs Usual Care After Exacerbation of COPD","status":"COMPLETED","sponsor":"my mhealth Ltd","startDate":"2015-06","conditions":"Chronic Obstructive Pulmonary Diseases","enrollment":40},{"nctId":"NCT02731846","phase":"PHASE3","title":"A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2016-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT01513460","phase":"PHASE3","title":"Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":773},{"nctId":"NCT01922271","phase":"PHASE4","title":"Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":152},{"nctId":"NCT01613326","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":657},{"nctId":"NCT01490125","phase":"PHASE3","title":"The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":247},{"nctId":"NCT01120691","phase":"PHASE3","title":"Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2224},{"nctId":"NCT00909779","phase":"PHASE3","title":"Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT01202188","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2144},{"nctId":"NCT01543828","phase":"PHASE4","title":"Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"COPD","enrollment":40},{"nctId":"NCT00557466","phase":"PHASE2","title":"A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"COPD","enrollment":568},{"nctId":"NCT00558285","phase":"PHASE2","title":"Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":257},{"nctId":"NCT01154127","phase":"PHASE3","title":"Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT01005901","phase":"PHASE3","title":"A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1324},{"nctId":"NCT00636961","phase":"PHASE2","title":"An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":27},{"nctId":"NCT00900731","phase":"PHASE3","title":"A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1598}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"COPD rescue medications","genericName":"COPD rescue medications","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"COPD rescue medications include NVA237 and tiotropium, which are used to treat patients with chronic obstructive pulmonary disease (COPD). These medications are studied for their efficacy, safety, and tolerability in clinical trials, such as the one comparing NVA237 to tiotropium.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}